Estimating the efficacy of the oral alkalizers in patients with chronic kidney disease.

Estimating the efficacy of the oral alkalizers in patients with chronic kidney disease. - Efficacy of the alkalizers on CKD. (CKOALA study)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010059

Enrollment

150

Registered

2013-02-26

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease.

Interventions

The oral alkalizer (1) is administered for six months. The oral alkalizer (2) is administered for six months. The standard treatment is done for six months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) A patient with chronic kidney disease and age >= 20. < 81 years. 2) Signed and dated informed consent document indicating that patient has been informed of all pertinent aspects of this trial prior to enrollment.

Exclusion criteria

Exclusion criteria: 1) Serious heart disease or liver disease. 2) Patients with alkaline urine. 3) Patients who are judged unfit to enroll in this trial by the investigator.

Design outcomes

Primary

Measure	Time frame
Serum creatinine level, eGFR, protein urea.	—

Countries

Japan

Contacts

Public ContactMichiaki Abe

Tohoku University Hospital Division of Nephrology, Endocrinology and Vascular Medicine.

michiabe@med.tohoku.ac.jp022-273-6289

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026